# Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

Study · id `cardio:ct-nct01516151` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01516151](<https://clinicaltrials.gov/study/NCT01516151>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01516151

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.

## Technical summary

Registry record NCT01516151. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 289 participants (enrolled count; ClinicalTrials.gov record NCT01516151, source copy `cardio:ctgov-nct01516151-2014-01-08`, retrieved 2026-10-31)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01516151, source copy `cardio:ctgov-nct01516151-2014-01-08`, retrieved 2026-10-31)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01516151, source copy `cardio:ctgov-nct01516151-2014-01-08`, retrieved 2026-10-31)
- Completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01516151, source copy `cardio:ctgov-nct01516151-2014-01-08`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT01516151, source copy `cardio:ctgov-nct01516151-2014-01-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01516151-2014-01-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
- Condition: Hypertriglyceridemia
- Intervention (Dietary supplement): CaPre™
- Intervention (Dietary supplement): CaPre™
- Intervention (Dietary supplement): CaPre™
- Intervention (Drug): Lipid Lowering Medication
- Intervention (Dietary supplement): CaPre™
- Lead sponsor: Grace Therapeutics Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: JSS Medical Research Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Grace Therapeutics Inc. (`cardio:org-grace-therapeutics-inc`)

## Provenance

Content hash: ddc91c3a00048d23a413e26e54d7c6b453f7401bbd6127710dbc1d832c15d32a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
